Pasca Sergiu
Pasca Sergiu
Verified email at
Cited by
Cited by
The silent healer: miR-205-5p up-regulation inhibits epithelial to mesenchymal transition in colon cancer cells by indirectly up-regulating E-cadherin expression
D Gulei, L Magdo, A Jurj, L Raduly, R Cojocneanu-Petric, A Moldovan, ...
Cell death & disease 9 (2), 1-16, 2018
SERS-based differential diagnosis between multiple solid malignancies: Breast, colorectal, lung, ovarian and oral cancer
V Moisoiu, A Stefancu, D Gulei, R Boitor, L Magdo, L Raduly, S Pasca, ...
International journal of nanomedicine 14, 6165, 2019
Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia
C Tomuleasa, S Fuji, C Berce, A Onaciu, S Chira, B Petrushev, WT Micu, ...
Frontiers in Immunology 9, 239, 2018
Role of key micronutrients from nutrigenetic and nutrigenomic perspectives in cancer prevention
AI Irimie, C Braicu, S Pasca, L Magdo, D Gulei, R Cojocneanu, C Ciocan, ...
Medicina 55 (6), 283, 2019
Exosome-carried microRNA-based signature as a cellular trigger for the evolution of chronic lymphocytic leukemia into Richter syndrome
A Jurj, L Pop, B Petrushev, S Pasca, D Dima, I Frinc, D Deak, ...
Critical Reviews in Clinical Laboratory Sciences 55 (7), 501-515, 2018
Antiproliferative effects of propofol and lidocaine on the colon adenocarcinoma microenvironment
T Tat, A Jurj, C Selicean, S Pasca, D Ionescu
J buon 24 (1), 106-115, 2019
MicroRNA-155 implication in M1 polarization and the impact in inflammatory diseases
S Pasca, A Jurj, B Petrushev, C Tomuleasa, D Matei
Frontiers in immunology 11, 625, 2020
LEAM vs. beam vs. CLV conditioning regimen for autologous stem cell transplantation in malignant lymphomas. retrospective comparison of toxicity and efficacy on 222 patients in …
A Colita, A Colita, H Bumbea, A Croitoru, C Orban, LE Lipan, OG Craciun, ...
Frontiers in Oncology 9, 892, 2019
KRAS/NRAS/BRAF mutations as potential targets in multiple myeloma
S Pasca, C Tomuleasa, P Teodorescu, G Ghiaur, D Dima, V Moisoiu, ...
Frontiers in Oncology 9, 1137, 2019
Targeting the microenvironment in MDS: the final frontier
P Teodorescu, S Pasca, D Dima, C Tomuleasa, G Ghiaur
Frontiers in Pharmacology 11, 1044, 2020
Minimal residual disease in chronic lymphocytic leukemia: a consensus paper that presents the clinical impact of the presently available laboratory approaches
C Tomuleasa, C Selicean, S Cismas, A Jurj, M Marian, D Dima, S Pasca, ...
Critical reviews in clinical laboratory sciences 55 (5), 329-345, 2018
Approach to the adult acute lymphoblastic leukemia patient
V Sas, V Moisoiu, P Teodorescu, S Tranca, L Pop, S Iluta, S Pasca, ...
Journal of Clinical Medicine 8 (8), 1175, 2019
A narrative review of central nervous system involvement in acute leukemias
D Deak, N Gorcea-Andronic, V Sas, P Teodorescu, C Constantinescu, ...
Annals of Translational Medicine 9 (1), 2021
Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?
C Constantinescu, S Pasca, T Tat, P Teodorescu, C Vlad, S Iluta, D Dima, ...
Journal for ImmunoTherapy of Cancer 8 (1), 2020
Persistent basophilia may suggest an “accelerated phase” in the evolution of CALR-positive primary myelofibrosis toward acute myeloid leukemia
J Dobrowolski, S Pasca, P Teodorescu, C Selicean, I Rus, M Zdrenghea, ...
Frontiers in Oncology 9, 872, 2019
Clinical approach to the patient in critical state following immunotherapy and/or stem cell transplantation: guideline for the on-call physician
C Constantinescu, C Bodolea, S Pasca, P Teodorescu, D Dima, I Rus, ...
Journal of Clinical Medicine 8 (6), 884, 2019
Medical application of hydrogen in hematological diseases
L Qian, Z Wu, J Cen, S Pasca, C Tomuleasa
Oxidative medicine and cellular longevity 2019, 2019
Hepatic Hydrothorax—An Independent Decompensating Event Associated with Long-Term Mortality in Patients with Cirrhosis
D Matei, R Craciun, D Crisan, B Procopet, T Mocan, S Pasca, R Zaharie, ...
Journal of Clinical Medicine 10 (16), 3688, 2021
Day 15 and day 33 minimal residual disease assessment for acute lymphoblastic leukemia patients treated according to the BFM ALL IC 2009 protocol: Single-center experience of …
LE Radu, A Colita, S Pasca, C Tomuleasa, C Popa, C Serban, ...
Frontiers in oncology 10, 923, 2020
Fibroblast dynamics as an in vitro screening platform for anti‐fibrotic drugs in primary myelofibrosis
C Tomuleasa, S Selicean, G Gafencu, B Petrushev, L Pop, C Berce, A Jurj, ...
Journal of Cellular Physiology 233 (1), 422-433, 2018
The system can't perform the operation now. Try again later.
Articles 1–20